These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 10064571

  • 1. The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy.
    Dehal SS, Brodie AM, Kupfer D.
    Drug Metab Dispos; 1999 Mar; 27(3):389-94. PubMed ID: 10064571
    [Abstract] [Full Text] [Related]

  • 2. Evidence that the catechol 3,4-Dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins.
    Dehal SS, Kupfer D.
    Cancer Res; 1996 Mar 15; 56(6):1283-90. PubMed ID: 8640815
    [Abstract] [Full Text] [Related]

  • 3. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation.
    Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A, Kupfer D.
    Drug Metab Dispos; 1993 Mar 15; 21(4):645-56. PubMed ID: 8104124
    [Abstract] [Full Text] [Related]

  • 4. Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins.
    Dehal SS, Kupfer D.
    Drug Metab Dispos; 1999 Jun 15; 27(6):681-8. PubMed ID: 10348797
    [Abstract] [Full Text] [Related]

  • 5. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
    Dehal SS, Kupfer D.
    Cancer Res; 1997 Aug 15; 57(16):3402-6. PubMed ID: 9270005
    [Abstract] [Full Text] [Related]

  • 6. Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation.
    Mani C, Kupfer D.
    Cancer Res; 1991 Nov 15; 51(22):6052-8. PubMed ID: 1933868
    [Abstract] [Full Text] [Related]

  • 7. Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome p450 induction by tamoxifen.
    Cotreau MM, von Moltke LL, Harmatz JS, Greenblatt DJ.
    Pharmacology; 2001 Nov 15; 63(4):210-9. PubMed ID: 11729359
    [Abstract] [Full Text] [Related]

  • 8. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation.
    Mani C, Hodgson E, Kupfer D.
    Drug Metab Dispos; 1993 Nov 15; 21(4):657-61. PubMed ID: 8104125
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin.
    Parte P, Kupfer D.
    Drug Metab Dispos; 2005 Oct 15; 33(10):1446-52. PubMed ID: 15987777
    [Abstract] [Full Text] [Related]

  • 11. Oxidative metabolism of monensin in rat liver microsomes and interactions with tiamulin and other chemotherapeutic agents: evidence for the involvement of cytochrome P-450 3A subfamily.
    Nebbia C, Ceppa L, Dacasto M, Carletti M, Nachtmann C.
    Drug Metab Dispos; 1999 Sep 15; 27(9):1039-44. PubMed ID: 10460804
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reduction in tamoxifen-induced CYP3A2 expression and DNA adducts using antisense technology.
    Mahadevan B, Arora V, Schild LJ, Keshava C, Cate ML, Iversen PL, Poirier MC, Weston A, Pereira C, Baird WM.
    Mol Carcinog; 2006 Feb 15; 45(2):118-25. PubMed ID: 16329150
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
    Ingle JN, Suman VJ, Johnson PA, Krook JE, Mailliard JA, Wheeler RH, Loprinzi CL, Perez EA, Jordan VC, Dowsett M.
    Clin Cancer Res; 1999 Jul 15; 5(7):1642-9. PubMed ID: 10430063
    [Abstract] [Full Text] [Related]

  • 15. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
    Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, Granneman GR.
    Drug Metab Dispos; 1999 Aug 15; 27(8):902-8. PubMed ID: 10421617
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L, Rosato A, Napoli E, Sola F, Geroni C, Floreani M, Zanovello P.
    Cancer Res; 2000 Jun 15; 60(12):3232-8. PubMed ID: 10866316
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism.
    Tang W, Stearns RA, Kwei GY, Iliff SA, Miller RR, Egan MA, Yu NX, Dean DC, Kumar S, Shou M, Lin JH, Baillie TA.
    J Pharmacol Exp Ther; 1999 Dec 15; 291(3):1068-74. PubMed ID: 10565826
    [Abstract] [Full Text] [Related]

  • 20. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
    Danie WA, Syrek M, Ryłko Z, Wójcikowski J.
    Pol J Pharmacol; 2001 Dec 15; 53(4):351-7. PubMed ID: 11990081
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.